Literature DB >> 22454324

Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data.

Marieke L Kuijjer1, Halfdan Rydbeck, Stine H Kresse, Emilie P Buddingh, Ana B Lid, Helene Roelofs, Horst Bürger, Ola Myklebost, Pancras C W Hogendoorn, Leonardo A Meza-Zepeda, Anne-Marie Cleton-Jansen.   

Abstract

High-grade osteosarcoma is a tumor with a complex genomic profile, occurring primarily in adolescents with a second peak at middle age. The extensive genomic alterations obscure the identification of genes driving tumorigenesis during osteosarcoma development. To identify such driver genes, we integrated DNA copy number profiles (Affymetrix SNP 6.0) of 32 diagnostic biopsies with 84 expression profiles (Illumina Human-6 v2.0) of high-grade osteosarcoma as compared with its putative progenitor cells, i.e., mesenchymal stem cells (n = 12) or osteoblasts (n = 3). In addition, we performed paired analyses between copy number and expression profiles of a subset of 29 patients for which both DNA and mRNA profiles were available. Integrative analyses were performed in Nexus Copy Number software and statistical language R. Paired analyses were performed on all probes detecting significantly differentially expressed genes in corresponding LIMMA analyses. For both nonpaired and paired analyses, copy number aberration frequency was set to >35%. Nonpaired and paired integrative analyses resulted in 45 and 101 genes, respectively, which were present in both analyses using different control sets. Paired analyses detected >90% of all genes found with the corresponding nonpaired analyses. Remarkably, approximately twice as many genes as found in the corresponding nonpaired analyses were detected. Affected genes were intersected with differentially expressed genes in osteosarcoma cell lines, resulting in 31 new osteosarcoma driver genes. Cell division related genes, such as MCM4 and LATS2, were overrepresented and genomic instability was predictive for metastasis-free survival, suggesting that deregulation of the cell cycle is a driver of osteosarcomagenesis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22454324     DOI: 10.1002/gcc.21956

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  57 in total

1.  Unstable genomes elevate transcriptome dynamics.

Authors:  Joshua B Stevens; Guo Liu; Batoul Y Abdallah; Steven D Horne; Karen J Ye; Steven W Bremer; Christine J Ye; Stephen A Krawetz; Henry H Heng
Journal:  Int J Cancer       Date:  2014-05-01       Impact factor: 7.396

2.  Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

Authors:  Laurie Sorenson; Yanfen Fu; Tressa Hood; Sarah Warren; Troy A McEachron
Journal:  Oncoimmunology       Date:  2019-06-27       Impact factor: 8.110

3.  HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.

Authors:  Mitali Das; Shyam Babu Prasad; Suresh Singh Yadav; Arusha Modi; Sunita Singh; Satyajit Pradhan; Gopeshwar Narayan
Journal:  Tumour Biol       Date:  2015-07-19

4.  The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression.

Authors:  Ritu Shekhar; Priyanka Priyanka; Praveen Kumar; Tanushree Ghosh; Md Muntaz Khan; Perumal Nagarajan; Sandeep Saxena
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

5.  Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Authors:  Jason A Somarelli; Samantha Shetler; Mohit K Jolly; Xueyang Wang; Suzanne Bartholf Dewitt; Alexander J Hish; Shivee Gilja; William C Eward; Kathryn E Ware; Herbert Levine; Andrew J Armstrong; Mariano A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2016-09-12       Impact factor: 4.272

6.  Genome-Informed Targeted Therapy for Osteosarcoma.

Authors:  Leanne C Sayles; Marcus R Breese; Amanda L Koehne; Stanley G Leung; Alex G Lee; Heng-Yi Liu; Aviv Spillinger; Avanthi T Shah; Bogdan Tanasa; Krystal Straessler; Florette K Hazard; Sheri L Spunt; Neyssa Marina; Grace E Kim; Soo-Jin Cho; Raffi S Avedian; David G Mohler; Mi-Ok Kim; Steven G DuBois; Douglas S Hawkins; E Alejandro Sweet-Cordero
Journal:  Cancer Discov       Date:  2018-09-28       Impact factor: 39.397

Review 7.  Cancer transcriptome profiling at the juncture of clinical translation.

Authors:  Marcin Cieślik; Arul M Chinnaiyan
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

8.  TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.

Authors:  Hitoshi Itoh; Tsuyoshi Kadomatsu; Hironori Tanoue; Masaki Yugami; Keishi Miyata; Motoyoshi Endo; Jun Morinaga; Eisuke Kobayashi; Takeshi Miyamoto; Ryoma Kurahashi; Kazutoyo Terada; Hiroshi Mizuta; Yuichi Oike
Journal:  Oncogene       Date:  2018-03-08       Impact factor: 9.867

9.  p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.

Authors:  Yong Ding; Yucai Wang; Jun Chen; Yunsheng Hu; Zhuo Cao; Pengcheng Ren; Yong Zhang
Journal:  Tumour Biol       Date:  2013-12-11

10.  Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation.

Authors:  Maya Kansara; Huei San Leong; Dan Mei Lin; Sophie Popkiss; Puiyi Pang; Dale W Garsed; Carl R Walkley; Carleen Cullinane; Jason Ellul; Nicole M Haynes; Rod Hicks; Marieke L Kuijjer; Anne-Marie Cleton-Jansen; Philip W Hinds; Mark J Smyth; David M Thomas
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.